有機合成化学協会誌
Online ISSN : 1883-6526
Print ISSN : 0037-9980
ISSN-L : 0037-9980
総説および総合論文
糖尿病治療薬CS-1036のハイブリッドプロセス開発
池内 豊林 政樹上田 剛原 学柴 陽一郎宮内 隆記
著者情報
ジャーナル 認証あり

2014 年 72 巻 5 号 p. 557-566

詳細
抄録
CS-1036 was a candidate compound for antidiabetic drug and synthesized with 3 key intermediates. The 5-membered iminocyclitol intermediate (C unit), one of the key intermediates for CS-1036 synthesis, was prepared by chemical synthesis in 12 steps previously. By using microbial metabolite, Nectrisine, as a starting material, the manufacturing process of C unit was shortened to 5 steps. Thus, the hybrid process between biological synthesis of Nectrisine and chemical synthesis from Nectrisine to C unit improved the productivity of C unit production dramatically. Nectrisine was originally purified with 2 ion-exchange chromatographies which posed disadvantage for large scale production to remove the residual protein impurities. The combination of denaturation by MeOH and crystallization from brine gave the important intermediate of C unit synthesis with high quality and yield without ion-exchange chromatographies.
著者関連情報
© 2014 社団法人 有機合成化学協会
前の記事 次の記事
feedback
Top